<DOC>
	<DOCNO>NCT00370890</DOCNO>
	<brief_summary>The purpose trial study benefit adjuvant chemotherapy use gemcitabine cisplatin high risk NPC patient residual EBV DNA follow primary radiotherapy without concurrent cisplatin .</brief_summary>
	<brief_title>A Trial Adjuvant Chemotherapy Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus ( EBV ) DNA Following Radiotherapy</brief_title>
	<detailed_description>- The standard treatment nasopharynx cancer course radiotherapy without concurrent chemotherapy . This cure 80 % patient . For 20 % develop recurrence metastasis , prognosis poor . - Elevated EBV-DNA plasma end radiotherapy show predict disease recurrence may marker subclinical residual disease . - This study aim test whether adjuvant treatment 6 cycle modern chemotherapy regimen ( gemcitabine cisplatin combination ) improve survival high risk patient nasopharynx cancer elevate EBV-DNA completion radiotherapy .</detailed_description>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Have give write informed consent , prior prestudy screening , understanding consent may withdraw time without prejudice . 2 . A histological diagnosis nasopharyngeal cancer ( NPC ) must establish time investigator must review confirm diagnosis prior randomization . 3 . Locoregional advance NPC UICC/AJCC Stages IIB , III , IVA IVB . 4 . No evidence distant metastasis stag work diagnosis . 5 . Must detectable plasma EBVDNA ( &gt; 0 copies/ml ) 68 week completion primary RT chemoRT 6 . No clinical evidence persistent locoregional disease primary treatment 7 . Performance status ECOG grade 0 1 . 8 . Patients must adequate organ marrow function define : leukocyte &gt; 3,000/L ; absolute neutrophil count &gt; 1,500/L ; platelet &gt; 100,000/L ; total bilirubin &lt; 1.5 X institutional upper limit normal ; AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 X institutional upper limit normal ; Creatinine clearance &gt; 50 ml/min 9 . At least 18 year age , either sex . 10 . If female , must either ( ) postmenopausal surgically sterilize , ( ii ) use hormonal contraceptive , intrauterine device , diaphragm spermicide duration study must neither pregnant breastfeeding . 1 . Hypercalcaemia : calcium &gt; = 2.7 mmol/L ( 10.8 mg/dL ) . 2 . Second primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin ) . 3 . More 12 week completion primary radiotherapy . 4 . Had receive prior adjuvant chemotherapy . 5 . Other serious concomitant systemic disorder incompatible study ( discretion investigator ) . 6 . Have serious active infection . 7 . Patients peripheral ototoxicity grade great 2 . 8 . Pregnant lactate female subject subject reproductive potential implementing adequate contraceptive measure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>nasopharyngeal cancer</keyword>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>EBV DNA</keyword>
	<keyword>PET CT scan</keyword>
</DOC>